Publication | Open Access
A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia
34
Citations
11
References
2008
Year
The recommended dose of bexarotene for future studies is 300 mg/m(2)/d. Bexarotene is well tolerated in patients with non-M3 AML and has evidence of antileukemic activity.
| Year | Citations | |
|---|---|---|
Page 1
Page 1